Christina Leslie and John Petrini
Announcement
By Jim Stallard, MA, Writer/Editor  |  Thursday, February 12, 2015

MSK’s Functional Genomics Initiative will enable basic scientists to take full advantage of the massive amount of data produced by tumor sequencing.

Epigenetics
Q&A
By Eva Kiesler, PhD, Science Writer/Editor  |  Friday, January 30, 2015

An experimental drug for acute myelogenous leukemia might potentially help many more patients than previously thought by controlling epigenetic processes, according to a recent MSK study.

Stained pathology slides of a patient’s tumor (right) and of an organoid made from that tumor (left).
In the Lab
By Christina Pernambuco-Holsten, MA, Managing Web Editor  |  Tuesday, December 30, 2014

From tropical plants and 3-D snapshots of worms to tiny particles that light up tumors, here’s a glimpse at some of the fascinating work MSK researchers pursued in 2014 as part of our quest to advance cancer science.

Pictured: Eytan Stein
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, December 11, 2014

An experimental drug for blood cancers with certain genetic mutations is showing promise in early-stage trials.

Cancer biologist Andrea Ventura
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, November 6, 2014

For the first time, Memorial Sloan Kettering scientists have created a mouse model that replicates a subtype of non-small cell lung cancer caused by a chromosomal rearrangement — a type of mutation that is common in cancers but thus far has been very difficult to study.

A student asks a question at last year’s "Major Trends” seminar.
Event
By Julie Grisham, MS, Science Writer/Editor  |  Monday, November 3, 2014

Every year, MSK gives high school students and their teachers the opportunity to learn about cutting-edge biomedical research from our scientists.

Pictured: Jorge Reis-Filho and Britta Weigelt
In the Lab
By Jim Stallard, MA, Writer/Editor  |  Tuesday, October 28, 2014

Genetic alterations linked to a rare salivary cancer could also shed light on more common malignancies.

DNA wrapped around histones
Decoder
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, October 14, 2014

Physician-scientist Omar Abdel-Wahab explains epigenetics, a growing field based on the study of genetic changes that are not part of the DNA code, and how it relates to cancer.

Pictured: Scott Lowe
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Tuesday, September 30, 2014

In taking a new approach to finding treatments for hepatocellular carcinoma, MSK scientists have uncovered a potential drug target for this highly aggressive cancer.

In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, September 4, 2014

Researchers have created tiny structures called organoids from patients’ prostate tumors. These organoids will allow the study of tumors in greater detail and enable correlation of genetic mutations with drug response.

Pictured: Johanna Joyce
In the Lab
By Jim Stallard, MA, Writer/Editor  |  Tuesday, August 19, 2014

A new study sheds light on what enables breast cancer cells to spread to the brain and presents a potential target for drugs.

In the Lab
By Jim Stallard, MA, Writer/Editor  |  Monday, August 11, 2014

Experimental pathologist Jorge Reis-Filho explains how tumor DNA obtained from the blood could lead to noninvasive — yet highly sensitive — ways of detecting and monitoring cancer in the body.

Lab mouse with cultured human pluripotent stem cells
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, August 7, 2014

Memorial Sloan Kettering researchers have developed a powerful new way to study human disease using stem cells whose genomes can be manipulated at will.

Pictured: Marc Ladanyi
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Wednesday, August 6, 2014

A newly discovered gene mutation appears to be the driving force behind a particularly aggressive form of embryonal rhabdomyosarcoma, a rare cancer of the skeletal muscle.

In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Monday, July 28, 2014

Memorial Sloan Kettering researchers have found a naturally occurring compound that can destroy cancer cells in mice by targeting MYC, a cancer-causing gene that has remained elusive until now.

Center News

Stay Informed

Get the latest information about cancer care and research every month.